Amicus Therapeutics Stock Today
| FOLD Stock | USD 10.71 0.11 1.02% |
Performance0 of 100
| Odds Of DistressLess than 44
|
Amicus Therapeutics is trading at 10.71 as of the 25th of April 2024, a -1.02 percent decrease since the beginning of the trading day. The stock's lowest day price was 10.68. Amicus Therapeutics has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Equity ratings for Amicus Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 31st of May 2007 | Category Healthcare | Classification Health Care |
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 295.38 M outstanding shares of which 31.32 M shares are currently shorted by private and institutional investors with about 9.84 trading days to cover. More on Amicus Therapeutics
Moving against Amicus Stock
| 0.71 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.7 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.65 | ELYM | Eliem Therapeutics | PairCorr |
| 0.63 | XFOR | X4 Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.54 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.54 | NRSNW | NeuroSense Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Amicus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Amicus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Amicus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| President CEO | Bradley MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Amicus Therapeutics report their recommendations after researching Amicus Therapeutics' financial statements, talking to executives and customers, or listening in on Amicus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Amicus Therapeutics. The Amicus consensus assessment is calculated by taking the average forecast from all of the analysts covering Amicus Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Amicus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Amicus Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Amicus Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amicus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Amicus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Amicus Therapeutics' financial leverage. It provides some insight into what part of Amicus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Amicus Therapeutics (FOLD) is traded on NASDAQ Exchange in USA. It is located in 47 Hulfish Street, Princeton, NJ, United States, 08542 and employs 517 people. Amicus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 3.16 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amicus Therapeutics's market, we take the total number of its shares issued and multiply it by Amicus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Amicus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 295.38 M outstanding shares of which 31.32 M shares are currently shorted by private and institutional investors with about 9.84 trading days to cover.
Amicus Therapeutics currently holds about 386.84 M in cash with (69.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.38.
Check Amicus Therapeutics Probability Of Bankruptcy
Ownership AllocationAmicus Therapeutics retains a total of 295.38 Million outstanding shares. The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Amicus Ownership Details
Amicus Stock Price Odds Analysis
What are Amicus Therapeutics' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Amicus Therapeutics jumping above the current price in 90 days from now is under 95%. The Amicus Therapeutics probability density function shows the probability of Amicus Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Amicus Therapeutics has a beta of 0.1805. This usually indicates as returns on the market go up, Amicus Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Amicus Therapeutics will be expected to be much smaller as well. Additionally, amicus Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Amicus Therapeutics to move above the current price in 90 days from now is under 95 (This Amicus Therapeutics probability density function shows the probability of Amicus Stock to fall within a particular range of prices over 90 days) .
Amicus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Amicus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Amicus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Amicus Therapeutics' value.| Instituion | Recorded On | Shares | |
| Palo Alto Investors, Llc | 2023-12-31 | 10.4 M | |
| Macquarie Group Ltd | 2023-12-31 | 7.2 M | |
| Pictet Asset Manangement Sa | 2023-12-31 | 7 M | |
| Geode Capital Management, Llc | 2023-12-31 | 6 M | |
| Deutsche Bank Ag | 2023-12-31 | 5.8 M | |
| Fiera Capital Corporation | 2023-12-31 | 5.1 M | |
| American Century Companies Inc | 2023-12-31 | 4.6 M | |
| Goldman Sachs Group Inc | 2023-12-31 | 4.2 M | |
| Northern Trust Corp | 2023-12-31 | 2.8 M | |
| Vanguard Group Inc | 2023-12-31 | 28.5 M | |
| Perceptive Advisors Llc | 2023-12-31 | 28.1 M |
Amicus Therapeutics Historical Income Statement
Amicus Therapeutics Income Statement is one of the three primary financial statements used for reporting Amicus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Amicus Therapeutics revenue and expense. Amicus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Amicus Therapeutics' Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Other Operating Expenses is expected to grow to about 496.5 M, whereas EBIT is forecasted to decline to (77.2 M). View More FundamentalsAmicus Stock Against Markets
Picking the right benchmark for Amicus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Amicus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Amicus Therapeutics is critical whether you are bullish or bearish towards Amicus Therapeutics at a given time. Please also check how Amicus Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Amicus Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Search Now
Equity SearchSearch for actively traded equities including funds and ETFs from over 30 global markets |
| All Next | Launch Module |
Amicus Therapeutics Corporate Directors
Amicus Therapeutics corporate directors refer to members of an Amicus Therapeutics board of directors. The board of directors generally takes responsibility for the Amicus Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Amicus Therapeutics' board members must vote for the resolution. The Amicus Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Robert Essner | Independent Director | Profile | |
| Craig Wheeler | Independent Director | Profile | |
| Burke Whitman | Independent Director | Profile | |
| Margaret McGlynn | Independent Director | Profile |
How to buy Amicus Stock?
Before investing in Amicus Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Amicus Therapeutics. To buy Amicus Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Amicus Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Amicus Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Amicus Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Amicus Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Amicus Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Amicus Stock please use our How to Invest in Amicus Therapeutics guide.
Already Invested in Amicus Therapeutics?
The danger of trading Amicus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Amicus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Amicus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Amicus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Amicus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.50) | Revenue Per Share 1.353 | Quarterly Revenue Growth 0.306 | Return On Assets (0.06) | Return On Equity (1.07) |
The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.